Edible Garden AG reported its 2025 financial results, highlighting growth in cut herbs and vitamin products, expanded retail distribution to nearly 6,000 stores, and strategic moves into higher-margin ready-to-drink (RTD) and shelf-stable consumer packaged goods. Despite a slight revenue decline due to shifting away from lower-margin produce, the company is investing heavily in scaling its RTD manufacturing with Tetra Pak integration to meet growing demand. This expansion aims to leverage Edible Garden's controlled environment agriculture foundation and national retail network to capture a large, underserved RTD market valued at $842.5 billion globally in 2025, projected to reach $1.26 trillion by 2033. The company expects improved gross margins and sustainable growth as new programs mature and volumes increase.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
